Search

Elizabeth Yeu, MD Surgeon Virginia Eye Consultants Norfolk, VA Disclosures: Grant/Research Support: Alcon; BioTissue; New World Medical; OSRX; Tarsus; Consultant: Adaptilens; Advanced Vision Group; Aldeyra; AbbVie; Aurion; Avellino; Bausch + [...]

The global central nervous system (CNS) therapeutics market is forecast to increase from USS80.25 ([euro]74.7 billion) in 2023 to US$106.19 billion ([euro]98.78 billion) by 2031, growing at a compound annual [...]

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck to $123 from $130 and keeps an Equal Weight rating on the shares. The Q3 reported highlighted ongoing [...]

Wells Fargo analyst Mohit Bansal lowered the firm's price target on Merck to $110 from $125 and keeps an Equal Weight rating on the shares. Merck's Gardasil expectation reset is [...]

BofA analyst Charlie Yang lowered the firm's price target on Merck to $120 from $140 and keeps a Buy rating on the shares. Q3 results modestly beat on the top [...]

Merck, a leading science and technology company, announced a Euro70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, [...]

FY24 consensus $7.74. Narrows FY24 revenue view to $63.6B-$64.1B from $63.4B-$64.4B, consensus [...]

Notable companies reporting before tomorrow's open, with earnings consensus, include Mastercard (MA), consensus $3.74... Merck (MRK), consensus $1.51... Uber (UBER), consensus 41c... Comcast (CMCSA), consensus $1.06... Eaton (ETN), consensus $2.80... [...]

Byline: Our Bureau, Bengaluru Merck, a global leader in science and technology, launched two engaging comic books in collaboration with Tinkle at Indian Institute of Science, Bengaluru. These books were [...]

Merck (MRK) and Moderna (MRNA) announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with Keytruda, Merck's anti-PD-1 [...]

Global Banking News-October 28, 2024-Merck and Moderna launch new Phase 3 trial for cancer vaccine (C)2024 ENPublishing - http://www.enpublishing.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD [...]

Barclays analyst Peter Lawson raised the firm's price target on Arcus Biosciences to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha data confirmed overall [...]

Citi analyst Geoff Meacham lowered the firm's price target on Merck to $130 from $140 and keeps a Buy rating on the shares following a transfer of analyst coverage. The [...]

DelveInsight reported its 'Schizophrenia Pipeline Insight 2024' report provides comprehensive global coverage of pipeline schizophrenia in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline [...]

Merck announced that the European Commission (EC) has approved two new indications for Keytruda, Merck's anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda, in combination with carboplatin [...]

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, [...]

Bernstein initiated coverage of Merck with a Market Perform rating and $115 price target. The firm initiated coverage on U.S. biopharma and is optimistic on the outlook for the industry. [...]

Global Banking News-October 16, 2024-Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease (C)2024 ENPublishing - http://www.enpublishing.co.uk Biopharmaceutical company Merck (NYSE: MRK), also known as MSD [...]

Merck announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE, at IDWeek 2024 in Los Angeles, California. The trial evaluated the immunogenicity, safety and tolerability of CAPVAXIVE compared to [...]

Stifel raised the firm's price target on Exelixis (EXEL) to $30 from $26 and keeps a Hold rating on the shares. The long-awaited ruling on the MSN Laboratories litigation is [...]

Exelixis (EXEL) and Merck (MRK) announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis' investigational tyrosine kinase inhibitor, or TKI, zanzalintinib with [...]

Global Banking News-October 14, 2024-Exelixis and Merck collaborate on clinical development of zanzalintinib (C)2024 ENPublishing - http://www.enpublishing.co.uk Oncology-focused biotech company Exelixis Inc (NASDAQ:EXEL) and US pharmaceutical company Merck & Co [...]

News / A fall from on high From party drug to psychedelic therapy 1912 MDMA, named for its chemical formula 3,4-methylene-dioxymethamphetamine, is first developed by pharmaceutical company Merck. 1960s and [...]

1912 MDMA, named for its chemical formula 3,4-methylene-dioxymethamphetamine, is first developed by pharmaceutical company Merck. 1960s and 1970s Psychologists explore using psychedelics, including LSD and MDMA, as enhancements to therapy. [...]

Truist analyst Srikripa Devarakonda lowered the firm's price target on Merck to $132 from $143 and keeps a Buy rating on the shares ahead of its Q3 results. The firm [...]

UBS analyst Trung Huynh lowered the firm's price target on Merck to $136 from $142 and keeps a Buy rating on the shares ahead of the Q3 earnings report. The [...]

After Johnson & Johnson (JNJ) announced that the company discontinued the SunRISe-2 trial, which evaluated TAR-200 + cetrelimab in muscle-invasive bladder cancer, or MIBC, patients due to the lack of [...]

Cantor Fitzgerald initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating. The firm says Bicara is Bicara is developing ficerafusp alfa, a first-in-class bifunctional antibody against estimated glomerular filtration [...]

Merck announced that the Phase 3 KEYNOTE-689 trial evaluating Keytruda - pembrolizumab -, Merck's anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, [...]

Qure.ai, a global healthcare AI company, has reported the completion of a $65 million Series D funding round. The company said the investment will expedite expansion into the US market [...]

Barclays analyst Carter Gould lowered the firm's price target on Merck to $140 from $142 and keeps an Overweight rating on the shares as part of an earnings preview for [...]

2024 OCT 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Biotechnology. According to news reporting out of [...]

Merck Animal Health, known as MSD Animal Health outside of the U.S. and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, reported the expansion of the newly [...]

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on cervical intraepithelial neoplasia are discussed in a new report. According to [...]

2024 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Research findings on Immunization and Public Health - Human Papillomavirus Vaccines are discussed in [...]

Merck Animal Health has announced the introduction of SENSEHUBCow Calf, remote monitoring technology designed to help optimize breeding results with less labor for cow/calf producers, including seedstock and club calf [...]

Guggenheim raised the firm's price target on Merus (MRUS) to $111 from $93 and keeps a Buy rating on the shares after the company announced dosing of the first patient [...]

Global Banking News-October 1, 2024-Merck acquires CN201 from Curon Biopharmaceutical (C)2024 ENPublishing - http://www.enpublishing.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, [...]

Merck announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor-like cytokine 1A, in [...]

Merck announced that the Japanese Ministry of Health, Labor and Welfare, or MHLW, has approved new indications for KEYTRUDA, or pembrolizumab, Merck's anti-PD-1 therapy, in certain lung and urothelial cancers: [...]

Merck announced that the Phase 3 KEYFORM-007 trial evaluating the investigational fixed-dose combination of favezelimab, Merck's anti-LAG-3 antibody, and pembrolizumab, or KEYTRUDA, Merck's anti-PD-1 therapy, did not meet its primary [...]

Global Banking News-September 25, 2024-Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers (C)2024 ENPublishing - http://www.enpublishing.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as [...]

Global Banking News-September 25, 2024-Merck's KEYFORM-007 trial fails to meet primary endpoint in colorectal cancer (C)2024 ENPublishing - http://www.enpublishing.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD [...]

Astellas Pharma (ALPMY) announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has approved Padcev with Merck's (MRK) Keytruda as a combination therapy for the first-line treatment of [...]

Merck Animal Health, a division of Merck, announced the expansion of the newly USDA-approved Nobivac NXT vaccine platform to include a best-in-class solution to protect cats against one of the [...]

JPMorgan sees Merck shares as 'highly attractive at current levels,' trading at 12-times estimated 2025 earnings. Merck has a number of catalysts that can drive outperformance over the next 6-12 [...]

Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted opinions recommending approval of Keytruda, Merck's anti-PD-1 therapy, for two indications in gynecologic [...]

Global Banking News-September 20, 2024-Merck's KEYTRUDA receives positive EU CHMP opinions for gynaecological cancers (C)2024 ENPublishing - http://www.enpublishing.co.uk US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside [...]

Stifel raised the firm's price target on Zoetis (ZTS) to $210 from $200 and keeps a Buy rating on the shares. Investors have been concerned about pending competition to Trio, [...]